| Objective: To observe the effect of butylphthalide injection on the serum level of matrix metalloproteinase-9(MMP-9)in patients with early acute cerebral infarction,and to explore the possible pharmacological mechanism of butylphthalide injection in the treatment of acute cerebral infarction.Methods: In the same period,60 patients with acute cerebral infarction within 24 hours after onset and 20 healthy patients were randomly selected.Enzyme-linked immunosorbent assay was used to detect serum MMP-9 levels in patients and healthy subjects.Sixty patients with acute cerebral infarction as cerebral infarction group(CI group)were divided into routine treatment group(CT group)and butylphthalide group(B group)with 30 cases each according to the randomized block method.Both groups were given lipid-regulating and anti-platelet therapy.Aggregation and symptomatic supportive care.Among them,the CT group was given 0.9% physiological saline 0.9g twice daily;Group B was given butylphthalide sodium chloride injection 25 mg twice daily.Serum MMP-9 levels were measured again at 48 hours of disease onset and seventh days of treatment.Both groups of patients were assessed for neurological deficits using the National Institutes of Health Stroke Scale(NIHSS)before treatment and on the seventh day of treatment.During the same period,20 healthy volunteers from the First People’s Hospital of Huaihua City were randomly selected as the healthy control group(Group C).The levels of serum MMP-9 in CI group and C group were observed;the level of MMP-9 before and after treatment in CT group and B group was changed;the level of MMP-9 was changed in CT group and B group in the seventh days of treatment;before and after seven days’ treatment in CT group and B group NIHSS score changes.The experimental results were statistically analyzed using the SPSS19.0 software package.Comparisons between the measurement data sets were performed using a group-designed t-test.Paired t tests were used before and after treatment.Results:1.Serum MMP-9 levels before treatment were significantly higher in CI group than in C group(602.21±97.6 ng/ml)and C group(163.07±52.7 ng/ml),the difference was statistically significant(P < 0.05).2.Serum levels of MMP-9 in the CT and B groups before treatment,48 hours after onset and seventh days of treatment are: CT group(595.28±92.63 ng/ml,625.83±89.26 ng/ml,283.62±29.9 ng/ml)Group B(610.48±104.21 ng/ml,624.35±91.87 ng/ml,266.23±22.16 ng/ml).The serum levels of MMP-9 at 48 hours after onset were mostly higher than before treatment(P > 0.05).There was no statistically significant difference.The serum levels of MMP-9 in the two groups before treatment,48 hours after onset and on the seventh day of treatment were lower than those before treatment and 48 hours after the onset(P < 0.05).The difference was statistically significant,and the decrease in the level of MMP-9 in group B was significantly higher than that in the CT group(P < 0.05 The difference was statistically significant.3.The NIHSS scores of group B and CT were lower than those before treatment 7 days after treatment,but the decrease of B component value was greater than that of CT group(P < 0.05).The difference was statistically significant.Before treatment,NIHSS scores were: group B(8.55±4.75 points),CT group(8.3±4.82 points),there was no significant difference between the two groups(P > 0.05).On the 7th day,NIHSS scores were: group B(5.45±3.73 points)and CT group(6.35±4.12 points).Conclusion: Butylphthalide injection improves neurological deficits in patients with early acute cerebral infarction,and its mechanism of action may be related to the reduction of serum MMP-9 levels. |
PDF Full Text Request